Company intelligence / Profile preview

Frequency Therapeutics

Lexington, Massachusetts, United Statesx.com ↗

Ownership: Public · FREQ
Employees: ~200
Development stage: Phase 2

Overview

Frequency Therapeutics develops regenerative medicines using its proprietary progenitor cell activation platform. Its lead program, FX‑322, has completed a Phase IIb trial targeting sensorineural hearing loss with results anticipated soon. A second candidate, FX‑345—designed to reach deeper into the cochlea—is in a Phase Ib safety study. The company also has a preclinical program aiming to activate oligodendrocyte precursor cells to promote remyelination in multiple sclerosis. Early clinical data have shown some promise but pivotal efficacy results are pending.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

FX-322

Phase 2

Indications: Sensorineural hearing loss

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $10.9M
Total revenue: $0
Enterprise value: $-61.9M

Beyond the preview

Go deeper on Frequency Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Frequency Therapeutics.

Explore the full profile